S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:TCON

TRACON Pharmaceuticals (TCON) Stock Price, News & Analysis

$0.43
+0.02 (+4.88%)
(As of 03/28/2024 ET)
Today's Range
$0.40
$0.46
50-Day Range
$0.15
$0.63
52-Week Range
$0.13
$2.19
Volume
3.11 million shs
Average Volume
7.26 million shs
Market Capitalization
$19.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

TRACON Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
830.7% Upside
$4.00 Price Target
Short Interest
Healthy
4.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of TRACON Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.20) to ($0.08) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.76 out of 5 stars

Medical Sector

702nd out of 939 stocks

Biological Products, Except Diagnostic Industry

115th out of 155 stocks

TCON stock logo

About TRACON Pharmaceuticals Stock (NASDAQ:TCON)

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

TCON Stock Price History

TCON Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Tracon Q4 2023 Earnings Preview
A Preview Of TRACON Pharma's Earnings
TRACON Pharmaceuticals, Inc. (TCON)
TCON TRACON Pharmaceuticals, Inc.
TRACON Pharmaceuticals Inc TCON
See More Headlines
Receive TCON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/05/2024
Today
3/29/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TCON
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$6.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+830.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-3,590,000.00
Pretax Margin
-29.79%

Debt

Sales & Book Value

Annual Sales
$12.05 million
Cash Flow
$0.09 per share
Book Value
($0.02) per share

Miscellaneous

Free Float
43,107,000
Market Cap
$19.56 million
Optionable
Optionable
Beta
0.80
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Charles P. Theuer M.D. (Age 60)
    Ph.D., Chairman, CEO & President
    Comp: $646.6k
  • Mr. Scott B. Brown CPA (Age 43)
    M.S., Chief Financial Officer
    Comp: $403.1k
  • Dr. James L. Freddo (Age 69)
    Chief Medical Officer
  • Mr. Ya Huang
    Executive Director of Statistical Programming

TCON Stock Analysis - Frequently Asked Questions

Should I buy or sell TRACON Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TCON shares.
View TCON analyst ratings
or view top-rated stocks.

What is TRACON Pharmaceuticals' stock price target for 2024?

3 Wall Street analysts have issued 1-year price targets for TRACON Pharmaceuticals' stock. Their TCON share price targets range from $3.00 to $6.00. On average, they anticipate the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 830.7% from the stock's current price.
View analysts price targets for TCON
or view top-rated stocks among Wall Street analysts.

How have TCON shares performed in 2024?

TRACON Pharmaceuticals' stock was trading at $0.1751 at the start of the year. Since then, TCON shares have increased by 145.5% and is now trading at $0.4298.
View the best growth stocks for 2024 here
.

Are investors shorting TRACON Pharmaceuticals?

TRACON Pharmaceuticals saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,900,000 shares, an increase of 323.4% from the February 29th total of 448,700 shares. Based on an average daily volume of 2,900,000 shares, the days-to-cover ratio is presently 0.7 days.
View TRACON Pharmaceuticals' Short Interest
.

When is TRACON Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our TCON earnings forecast
.

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) announced its earnings results on Tuesday, March, 5th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.03) by $0.04. The biopharmaceutical company had revenue of $3.41 million for the quarter, compared to the consensus estimate of $3 million.

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

When did TRACON Pharmaceuticals IPO?

TRACON Pharmaceuticals (TCON) raised $47 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

Who are TRACON Pharmaceuticals' major shareholders?

TRACON Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (0.84%), Vanguard Group Inc. (0.84%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Charles Theuer, Opaleye Management Inc, Saundra L Pelletier and Scott B Brown.
View institutional ownership trends
.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TCON) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners